Analysts Set Expectations for Brainsway FY2025 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities research analysts at Northland Securities cut their FY2025 EPS estimates for shares of Brainsway in a report released on Wednesday, March 4th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings of $0.09 per share for the year, down from their previous estimate of $0.17. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q4 2025 earnings at $0.02 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.04 EPS.

A number of other research analysts have also recently commented on BWAY. Wall Street Zen cut shares of Brainsway from a “buy” rating to a “hold” rating in a research report on Friday, January 23rd. HC Wainwright increased their price objective on shares of Brainsway from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Brainsway Stock Up 1.4%

BWAY stock opened at $12.62 on Friday. Brainsway has a 52-week low of $3.92 and a 52-week high of $13.31. The stock has a market cap of $494.96 million, a price-to-earnings ratio of 84.13 and a beta of 1.20. The business has a fifty day moving average of $11.69 and a two-hundred day moving average of $9.29.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BWAY. NewEdge Advisors LLC boosted its stake in shares of Brainsway by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after buying an additional 7,549 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Brainsway in the second quarter valued at $85,000. Eagle Global Advisors LLC increased its position in shares of Brainsway by 19.3% in the third quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company’s stock valued at $1,120,000 after buying an additional 12,000 shares in the last quarter. Huntleigh Advisors Inc. raised its stake in shares of Brainsway by 6.3% during the 3rd quarter. Huntleigh Advisors Inc. now owns 82,265 shares of the company’s stock worth $1,240,000 after buying an additional 4,849 shares during the last quarter. Finally, Essex Investment Management Co. LLC boosted its position in shares of Brainsway by 3.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock worth $4,682,000 after buying an additional 9,744 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.